Neurotrope, Inc. (OTCQB: NTRP): today announced that Paula T. Trzepacz, M.D., has joined Neurotrope BioScience, Inc., the Company's wholly owned operating subsidiary, as its Executive Vice President and Chief Medical Officer.
Prior to joining Neurotrope, Dr. Trzepacz was at Eli Lilly and Company for over 15 years where she was most recently a Senior Medical Fellow in Neurosciences drug development. She served on the global drug development team for Amyvid, the PET radiotracer indicated for estimation of beta-amyloid plaque density in brains of cognitively impaired persons suspected of having Alzheimer's disease. Prior to that, she led the Phase 2 medical team investigating mibampator, a novel AMPA receptor potentiator, for agitation and aggression in Alzheimer's disease patients. As Senior Medical Fellow on the global Strattera team for over three years Dr. Trzepacz was the medical lead for registration and regulatory related issues for its Attention Deficit Hyperactivity Disorder indications for both adult and pediatric populations, including design of new Phase 3 registration trials and collaborations with the European and Japanese Lilly teams. As Senior Medical Director of U.S. Neurosciences, she was responsible for a large medical team of physicians and other scientists including for the design and execution of many Phase 4 double-blind, randomized placebo-controlled clinical trials over a five year period. Some of those trials were used to support registration work in addition to answering key patient-relevant questions for practicing physicians. Importantly, the products her team supported included Prozac, Zyprexa, Cymbalta, and Strattera and their multiple indications, line extensions, and formulations.
Dr. Trzepacz is a geriatric psychiatrist and neuropsychiatrist. She is currently Clinical Professor of Psychiatry atIndiana University School of Medicine where she has served since 2004. In the past Dr. Trzepacz was Associate Professor of Psychiatry and Neurology at the University of Pittsburgh School of Medicine and Professor of Psychiatry and Neurology at the University of Mississippi Medical School, where she directed clinical services and participated in NIH-funded research. She served as President of the American Neuropsychiatric Association in 2009-2011 and of the Academy of Psychosomatic Medicine in 2004-2005. Dr. Trzepacz serves on four journal editorial boards, most recently joining "Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring." Dr. Trzepacz earned her B.A. at Wellesley College and M.D. at Geisel School of Medicine at Dartmouth College. After a year of Internal Medicine residency she completed a Psychiatry residency and Consultation-Liaison Psychiatry Fellowship at Dartmouth.
"We are pleased to welcome Paula to the Neurotrope team as our Chief Medical Officer," said Charles S. Ramat, President and Chief Executive Officer of Neurotrope. "Paula has a demonstrated track record of success in leading clinical development efforts in multiple therapeutic areas, most importantly Alzheimer's disease and other neurological disorders in adult and pediatric populations and has a strong academic medicine background. This broad clinical research expertise will be invaluable to Neurotrope as we continue advancing and expanding our pipeline of Bryostatin and Bryologs."
About Neurotrope
Neurotrope BioScience, Inc., a wholly owned subsidiary of Neurotrope, Inc., is at the forefront of biotechnology companies having a focus on developing a novel therapy for the treatment of moderately severe to severe Alzheimer's disease. The scientific basis of our treatment is activation of Protein Kinase C isozymes ? and ? by bryostatin, a natural product, which can result in repair of damaged synapses as well as synaptogenesis, reduction of toxic amyloid generation, and enhancement of memory and learning, thus having the potential to improve cognition and behavior in Alzheimer's disease.
